[ CAS No. 153035-62-2 ] {[proInfo.proName]}

Name: 153035-62-2|(4'-Ethyl-[1,1'-biphenyl]-4-yl)boronic acid|97%
Brand: Ambeed
SKU: A127185
Price: 11.0 USD
Availability: InStock
Rating: 92 (26 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 153035-62-2 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 153035-62-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 153035-62-2 ]

SDS Specification

Alternatived Products of [ 153035-62-2 ]

Product Details of [ 153035-62-2 ]

CAS No. :	153035-62-2	MDL No. :	MFCD04038068
Formula :	C₁₄H₁₅BO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	DEUOTLGHQXNPJY-UHFFFAOYSA-N
M.W :	226.08	Pubchem ID :	45789738
Synonyms :

Calculated chemistry of [ 153035-62-2 ] Expand+

Physicochemical Properties

Num. heavy atoms :	17
Num. arom. heavy atoms :	12
Fraction Csp3 :	0.14
Num. rotatable bonds :	3
Num. H-bond acceptors :	2.0
Num. H-bond donors :	2.0
Molar Refractivity :	71.48
TPSA :	40.46 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	Yes
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.37 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.0
Log Po/w (XLOGP3) :	3.25
Log Po/w (WLOGP) :	1.6
Log Po/w (MLOGP) :	2.41
Log Po/w (SILICOS-IT) :	1.74
Consensus Log Po/w :	1.8

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.61
Solubility :	0.055 mg/ml ; 0.000243 mol/l
Class :	Soluble
Log S (Ali) :	-3.77
Solubility :	0.0381 mg/ml ; 0.000169 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.61
Solubility :	0.00561 mg/ml ; 0.0000248 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.05

Safety of [ 153035-62-2 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 153035-62-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 153035-62-2 ]

[ 153035-62-2 ] Synthesis Path-Downstream 1~17

1
[ 937175-83-2 ]
[ 153035-62-2 ]
[ 943604-11-3 ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate;5%-palladium/activated carbon; In ethanol; water; toluene; for 6.0h;Heating / reflux;	A mixture of 3.3 g (10.2 mmol) of the compound (E-4) obtained above, 2.8 g (12.3 mmol) of 4'-ethylbiphenyl-4-yl dihydroxyborane, 3.2g (15.4 mmol) of potassium carbonate, 0.2 g of 5%-Pd/C and 50 mL of a mixed solvent of toluene, ethanol and water (ratio: 1/1/1) was refluxed for 6 hours to obtain a reaction solution. After removing the catalyst by filtration, 50 mL of toluene was added to the reaction solution, which was then washed with water. The reaction solution having been washed with water was dried over anhydrous magnesium sulfate, and the solvent was distilled off from the reaction solution under reduced pressure to obtain 6.4 g of a residue. The residue was purified by silica gel column chromatography (eluent: toluene/ethyl acetate = 15/1) to obtain 3.1 g of crude crystals of the compound (E-5). The crude crystals were dissolved in a mixed solvent of ethanol and ethyl acetate (ratio: 8/2) and recrystallized therefrom to obtain 2.4 g of purified crystals of the compound (E-5).

Reference： [1]Patent: EP1970362,2008,A1 .Location in patent: Page/Page column 24-26

2
[ 153035-62-2 ]
(S)-ethyl 2-(5-bromo-4-(4,4-dimethylpiperidin-1-yl)-2,6-dimethylpyridin-3-yl)-2-(tert-butoxy)acetate [ No CAS ]
(S)-ethyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4'-ethyl[1,1'-biphenyl]-4-yl)-2,6-dimethylpyridin-3-yl)acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
59.3%	With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In N,N-dimethyl-formamide; at 110.0℃; for 2.0h;Inert atmosphere;	(S)-Ethyl 2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-l-yl)-5-(4'-ethyl-[l '-bip yl)-2, 6-dimethylpyridin-3-yl)acetate: A mixture of (S)-ethyl 2-(5-bromo-4-(4,4- dimethylpiperidin-l-yl)-2,6-dimethylpyridin-3-yl)-2-(tert-butoxy)acetate (0.0381 g, 0.084 mmol), (4'-ethyl-[l,r-biphenyl]-4-yl)boronic acid (0.028 g, 0.125 mmol) and 2M Na2C03 (0.105 ml, 0.209 mmol) in DMF (2 mL) was degassed for 10 min. Then, Pd(Ph3P)4 (9.67 mg, 8.37 mupiiotaomicron) added, degassed for 5 min and placed in a pre-heated oil bat at 110 C. After 2 h, cooled and purified by prep-HPLC to afford (S)-ethyl 2-(tert-butoxy)-2-(4-(4,4- dimethylpiperidin- 1 -yl)-5-(4'-ethyl-[ 1 , 1 '-biphenyl]-4-yl)-2,6-dimethylpyridin-3 -yl)acetate (0.0276 g, 0.050 mmol, 59.3 % yield) as white solid. 1H NMR (500 MHz, CDC13) delta 7.69 (ddd, J=1.8, 7.9, 13.8 Hz, 2H), 7.60-7.64 (m, 2H), 7.32-7.36 (m, 3H), 7.24 (dd, J=1.7, 7.8 Hz, 1H), 6.09 (br. s., 1H), 4.24-4.32 (m, 1H), 4.19 (qd, J=7.1, 10.7 Hz, 1H), 3.22 (br. s., 1H), 2.93 (br. s., 1H), 2.75 (q, J=7.6 Hz, 2H), 2.64 (s, 3H), 2.29-2.36 (m, 1H), 2.27 (s, 3H), 2.03-2.13 (m, 1H), 1.50-1.58 (m, 1H), 1.35-1.41 (m, 1H), 1.32 (t, J=7.6 Hz, 3H), 1.28 (t, J=7.3 Hz, 3H), 1.22 (s, 9H), 1.01-1.11 (m, 1H), 0.89 (br.s, 3H), 0.62 (br. s., 3H). One proton of piperidine was not resolved. LCMS (M+H) = 557.4.

Reference： [1]Patent: WO2017/6281,2017,A1 .Location in patent: Page/Page column 58

3
[ 75-68-3 ]
[ 153035-62-2 ]
4-(1,1-difluoroethyl)-4'-ethyl-1,1'-biphenyl [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
58%	With dmap; bis(triphenylphosphine)nickel(II) chloride; 4,4'-Dimethoxy-2,2'-bipyridin; potassium carbonate; In 1,2-dimethoxyethane; at 110.0℃; for 5.0h;Schlenk technique; Inert atmosphere;	To a 10 ml Schlenk reaction tube was charged reactant 2b (0.2 mmol), catalyst NiCl2(PPh3)2 (3 mol%), ligand 4,4 '-dimethoxy-2,2 '-bipyridine ( 3 mol%), alkali K2CO3 (2.0 eq.) additive DMAP (70 mol%), vacuum-exchanged with nitrogen, will dissolve the DME solution of reactant 1 (pre-reaction ready, transfer reactant 1 slowly to DME, to total The volume was not increased, and the concentration was 1.3 mol/L by 19F NMR, and the reaction was carried out at 110 C for 5 h. TLC was used to detect the progress of the reaction. After the reaction is completed, silica gel is directly added, and the column chromatography is carried out by spin-drying to obtain the target product 3b (58%).

Reference： [1]RSC Advances,2019,vol. 9,p. 28409 - 28413
[2]Patent: CN109704914,2019,A .Location in patent: Paragraph 0031; 0032; 0049

4
[ 153035-62-2 ]
[ 1073-06-9 ]
[ 204776-88-5 ]